在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human tumor necrosis factor superfamily 15 (TL1A/TNFSF15) ELISA Kit

Human tumor necrosis factor superfamily 15 (TL1A/TNFSF15) ELISA Kit

  • 中文名稱：
    人腫瘤壞死因子超家族15(TL1A/TNFSF15)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E15770h
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人腫瘤壞死因子超家族15(TL1A/TNFSF15)酶聯(lián)免疫試劑盒（CSB-E15770h）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織培養(yǎng)上清液、組織勻漿樣本中的TNFSF15含量。TNFSF15 是一個備受關(guān)注的靶點(diǎn)。它在免疫系統(tǒng)等生理過程中扮演重要角色。研究機(jī)制方面，其可能通過與特定受體結(jié)合，調(diào)控細(xì)胞的生長、分化和凋亡等，在炎癥、腫瘤等疾病的發(fā)生發(fā)展中起到一定作用，為相關(guān)疾病治療提供潛在方向。試劑盒檢測范圍為0.78 ng/mL-50 ng/mL，本產(chǎn)品在炎癥機(jī)制研究、藥物靶點(diǎn)驗(yàn)證、生物標(biāo)志物篩選等方向具有重要應(yīng)用價(jià)值，為探索TL1A在免疫調(diào)控網(wǎng)絡(luò)中的作用提供了高靈敏度的檢測方案，實(shí)驗(yàn)數(shù)據(jù)可為相關(guān)領(lǐng)域的分子機(jī)制研究提供可靠依據(jù)。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    TNFSF15; TL1; VEGI; Tumor necrosis factor ligand superfamily member 15; TNF ligand-related molecule 1; Vascular endothelial cell growth inhibitor
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, cell culture supernates, tissue homogenates
  • 檢測范圍：
    0.78 ng/mL-50 ng/mL
  • 靈敏度：
    0.195 ng/mL
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Others
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%        
    Three samples of known concentration were tested twenty times on one plate to assess.    
    Inter-assay Precision (Precision between assays): CV%<10%        
    Three samples of known concentration were tested in twenty assays to assess.      
                   
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human TL1A/TNFSF15 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
    　 Sample Serum(n=4)    
    1:1 Average % 90    
    Range % 85-93    
    1:2 Average % 97    
    Range % 92-100    
    1:4 Average % 94    
    Range % 86-97    
    1:8 Average % 100    
    Range % 89-105    
  • 回收率：
    The recovery of human TL1A/TNFSF15 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
     
    Sample Type Average % Recovery Range    
    Serum (n=5) 101 92-106    
    EDTA plasma (n=4) 101 95-104    
                   
                   
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
     
    ng/ml OD1 OD2 Average Corrected    
    50 2.471 2.397 2.434 2.295    
    25 1.890 1.792 1.841 1.702    
    12.5 1.259 1.223 1.241 1.102    
    6.25 0.841 0.832 0.837 0.698    
    3.12 0.469 0.455 0.462 0.323    
    1.56 0.324 0.314 0.319 0.180    
    0.78 0.229 0.218 0.224 0.085    
    0 0.141 0.137 0.139 　    
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價(jià)

靶點(diǎn)詳情

  • 功能：
    Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis.
  • 基因功能參考文獻(xiàn)：
    1. TNFSF15 polymorphisms may contribute to genetic susceptibility of inflammatory bowel disease (Meta-Analysis) PMID: 29873318
    2. TL1A modulated Rheumatoid arthritis-fibroblast-like synoviocytes migration and Indian hedgehog signaling pathway using TNFR2. PMID: 29748156
    3. TL1A can induce tumor cell proliferation and promote the occurrence of colitis-associated colorectal cancer by activating Wnt/beta-catenin pathway. PMID: 29796912
    4. TNFSF15, a cytokine mainly produced by blood endothelial cells, facilitates tumor lymphangiogenesis by upregulating VEGFC expression in A549 cells. PMID: 29890027
    5. Results suggested that TNFSF15 (rs3810936 and rs4979462) SNPs may confer susceptibility to systemic lupus erythematosus (SLE) risk, which were significantly associated with the clinical phenotypes of SLE. PMID: 29803925
    6. Three alternatively spliced isoforms of VEGI, VEGI174, VEGI192 and VEGI251 have been documented. This study investigated the effects of VEGI174 and its functional domains (V7 and V8) on epithelialmesenchymal transition (EMT) in renal cell carcinoma (RCC) cells in vitro. Overexpression of VEGI174, V7 or V8 inhibited EMT. PMID: 28656288
    7. Results provide evidence that variance within TNFSF15 has the potential to affect cytokine expression across a range of tissues and thereby contribute to protection from infectious diseases such as leprosy, while increasing the risk of immune-mediated diseases including Crohn's disease and primary biliary cholangitis. PMID: 27507062
    8. single variant analysis detected a previously unreported psoriasis risk locus at TNFSF15 (rs6478108) PMID: 28973304
    9. play a role in the development of systemic sclerosis PMID: 28397078
    10. the DR3/TL1A pathway directly enhances human OC formation and resorptive activity, controlling expression and activation of CCL3 and MMP-9. PMID: 28062298
    11. the blocking of tumor necrosis factor receptor 2 (TNFR2) decreased TL1A-stimulated IL-6 production by rheumatoid arthritis fibroblast-like synoviocytes. PMID: 27081759
    12. Distinct but overlapping TNFSF15 haplotypes were demonstrated in diverticulitis patients versus healthy controls when compared with the known Crohn's risk haplotype suggesting similar but distinct genetic predispositions. This study strengthens the role for a genetic predisposition to diverticulitis that involves the TNFSF15 gene. PMID: 28624054
    13. TL1A differentially induces expression of TH17 effector cytokines IL-17, -9, and -22 and provides a potential target for therapeutic intervention in TH17-driven chronic inflammatory diseases. PMID: 27733581
    14. Our findings indicate that VEGI174 prevents progression and tumor metastasis through inhibiting epithelial-mesenchymal transition (EMT) in renal cell carcinoma (RCC) in vivo. This may provide a new approach for the treatment of RCC PMID: 28739718
    15. Data suggest that human regulatory T-lymphocytes express DR3 and demonstrate DR3/TL1A-mediated activation of signaling via MAP kinases and NFkappaB. (DR3 = death receptor 3; TL1A/TNFSF15 = tumor necrosis factor [ligand] superfamily, member 15) PMID: 28337757
    16. These results raise the possibility for involvement of TL1A/DR3/DR3-mediated mechanisms in epithelial-mesenchymal interactions and the development of inflammation-induced intestinal fibrosis in Crohn's disease. PMID: 27665176
    17. rs1250569 (ZMIZ1) and rs10114470 (TL1A) are two novel loci that indicate susceptibility to Inflammatory Bowel Disease in Han-Chinese patients. PMID: 28456797
    18. results support an idea that the genetic susceptibility of TNFSF15 to CD may be confounded, in part, by the increase of Prevotella PMID: 28197769
    19. (188)Re-NGR-VEGI has the potential as a theranostic agent. PMID: 26768609
    20. miRNA-31 can directly bind to the 3-UTR of TNFSF15, thereafter negatively regulating its expression in Caco2 cells. PMID: 27188743
    21. There were significant associations of rs3810936, rs6478108, rs6478109, rs7848647 with CD in Korean pediatric patients (P = 6.5x10(-8), P = 1.3x10(-8), P = 3.7x10(-8), P = 2.9x10(-8), respectively). PMID: 25998826
    22. Patients with mild traumatic brain injury (TBI) exhibited higher VEGI levels than those with moderate and severe TBI. PMID: 26945876
    23. Biologics beyond TNF-alpha inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders. PMID: 26810853
    24. Rs3810936 of TNFSF15 were related to the risk of ankylosing spondylitis PMID: 26823868
    25. Higher TL1A levels were associated with early stage chronic lymphocytic leukemia. PMID: 26393680
    26. TL1A-induced cell death is directly mediated through DR3. PMID: 26509650
    27. Plasma levels of TL1A were significantly higher in newly diagnosed SLE patients compared with controls, and were positively associated with SLE disease activity index. PMID: 25929716
    28. This study indicates that the HDAC inhibitor may be exploited as a therapeutic strategy modulating the soluble VEGI/DR3 pathway in osteosarcoma patients PMID: 25778932
    29. Results show that subjects with TNFSF15 -358CC genotype were at higher risks for developing gastric adenocarcinoma in the Helicobacter pylori infected group. PMID: 25251497
    30. The data indicate that TL1A may contribute to pathogenesis of inflammatory bowel diseases via local but not systemic induction of IL-17A but not IL-4, IL-13 or IFN-gamma. PMID: 26072972
    31. study has defined the increased serum and SF samples levels of TL1A and DcR3 in patients with rheumatoid arthritis (RA); findings support the hypothesis that TL1A and DcR3 may contribute to the pathogenesis of RA PMID: 25647275
    32. TNFSF15 SNPs, rs6478108 and rs4574921, may be independent genetic predictive factors for the development of stricture/non-perianal penetrating complications and perianal fistula, respectively. PMID: 24835165
    33. TL1A increases expression of CD25, LFA-1, CD134 and CD154, and induces IL-22 and GM-CSF production from effector CD4 T-cells PMID: 25148371
    34. Addition of TL1A to IL-1beta + IL-23 also augmented ILC3 proliferation PMID: 26046454
    35. This study shows an association between TNFSF15-rs3810936 and AAU and suggests that the TL1A/DR3 pathway may be implicated in the pathogenesis of this disease. PMID: 26200500
    36. associations exist between TNFSF15 gene polymorphisms and IBD (both CD and UC) in the Indian population PMID: 25501099
    37. These results suggested that TL1A could promote Th17 differentiation in rheumatoid arthritis via the activation of RORc, and this effect may be mediated by the binding of TL1A with DR3. PMID: 24832108
    38. TL1A blood levels are elevated in psoriasis patients; TL1A expression is higher in psoriatic lesions than in normal skin PMID: 25908025
    39. Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1. PMID: 25899471
    40. Soluble TL1A synergized with IL-23 to stimulate peripheral blood mononuclear cells from patients with psoriasis vulgaris to produce IL-17. PMID: 25200589
    41. This meta-analysis indicated that most of the seven TNFSF15 polymorphisms (except for rs4263839) were risk factors contributed to CD and UC susceptibility. The differences in ethnicity did not influence the risk obviously. PMID: 25028192
    42. DR3 is expressed in some interstitial vascular endothelial cells (EC) in human kidney in situ; these EC also respond to its ligand TL1A by activating NF-kappaB. PMID: 25399326
    43. Mechanisms mediating TNFSF15:DR3 contributions to pattern recognition receptor outcomes included TACE-induced TNFSF15 cleavage to soluble TNFSF15; soluble TNFSF15 then led to TRADD/FADD/MALT-1- and caspase-8-mediated autocrine IL-1 secretion. PMID: 25197060
    44. This is the first report of the association between early Crohn's disease and the TNFSF15 single nucleotide polymorphisms. PMID: 25664710
    45. Tumor-infiltrating natural killer and CD4(+) T cells under the influence of cancer cells significantly increase the production of IFNgamma, which in turn inhibits TNFSF15 expression in vascular endothelial cells. PMID: 24141405
    46. may play an important role in the pathogenesis of primary biliary cirrhosis PMID: 24016146
    47. Our data demonstrate a key role for TL1A in promoting ILC2s at mucosal barriers. PMID: 24220298
    48. Combining the genetic marker TNFSF15 with ASCA IgA increased the power of predicting stenosis/perforating phenotype in Crohn's disease patients with TNFSF15 but not with a NOD2 genetic background PMID: 24783249
    49. genetic polymorphism is associated with psoriasis and psoriatic arthritis in Hungarians PMID: 24269700
    50. attenuated S. typhimurium carrying the dual function plasmid VEGI151/survivin cannot only be specifically enriched in the tumor tissue, but also showed a synergistic antitumor effect in vivo. PMID: 23404494

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Membrane; Single-pass type II membrane protein.; [Tumor necrosis factor ligand superfamily member 15, secreted form]: Secreted.
  • 蛋白家族：
    Tumor necrosis factor family
  • 組織特異性：
    Specifically expressed in endothelial cells. Detected in monocytes, placenta, lung, liver, kidney, skeletal muscle, pancreas, spleen, prostate, small intestine and colon.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 11931

    OMIM: 604052

    KEGG: hsa:9966

    STRING: 9606.ENSP00000363157

    UniGene: Hs.23349



主站蜘蛛池模板： 国产一区二区三区四区五区加勒比| 人人爽人人爱| 国产精品亚洲а∨天堂2021| 全部av―极品视觉盛宴| 久久大蕉香蕉免费| 137肉体摄影日本裸交| 污污污www精品国产网站| 亚洲精品一区二区三区婷婷月| 综合久久久久6亚洲综合| 五 月 丁 香 综合中文| 精品久久久久久| 国产精品igao视频网网址| 亚洲国产成人精品无码一区二区| 囯产精品一区二区三区线| 最近更新中文字幕| 国产 精品 自在 线免费| 日韩av无码一区二区三区无码| 免费无码国产欧美久久18| 国产乡下妇女做爰| 忍着娇喘人妻被中出中文字幕| 未满十八18禁止午夜免费网站| 国产裸体舞一区二区三区 | 女人大荫蒂毛茸茸视频| 小宝贝荡货啊用力水湿aⅴ视频| 国产成人无码av大片大片在线观看| 国精产品一区一区三区| 人人做人人爽人人爱| 国产精品午夜福利不卡120| 国产精品亚洲a∨天堂不卡| 啦啦啦www播放日本观看| 男女野外做爰全过程69影院| 亚洲精品久久久无码大桥未久| 日本在线视频www鲁啊鲁| 欧美丰满大乳大屁股流白浆| 久久久久精品无码一区二区三区| 国产吃奶在线观看| 国产精品免费精品自在线观看| 亚洲久热中文字幕在线| 婷婷综合缴情亚洲| 肥老熟妇伦子伦456视频| 亚洲成aⅴ人片久青草影院|